← Back to Screener
Aligos Therapeutics, Inc. Common Stock (ALGS)
Price$4.91
Value ScoreB
Growth ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-57.23%
Price vs S&P 500 (4W)-14.93%
VGM Score64.03
Market Capitalization$30.38M
All Metrics
Book Value / Share (Quarterly)$5.14
P/TBV (Annual)0.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-46.04%
Cash Flow / Share (Quarterly)$-13.77
Price vs S&P 500 (YTD)-53.73%
Net Profit Margin (TTM)-1919.68%
EPS (TTM)$-8.70
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-8.70
EPS (Annual)$-2.45
ROI (Annual)-45.06%
Net Profit Margin (5Y Avg)-1726.24%
Cash / Share (Quarterly)$8.87
Revenue Growth QoQ (YoY)809.97%
ROA (Last FY)-27.33%
Revenue Growth TTM (YoY)43.88%
EBITD / Share (TTM)$-9.11
ROE (5Y Avg)-70.33%
Operating Margin (TTM)-2033.39%
Cash Flow / Share (Annual)$-13.42
P/B Ratio0.96x
P/B Ratio (Quarterly)1.45x
Net Income / Employee (Annual)$-295,000
EV / Revenue (TTM)0.10x
ROA (TTM)-90.88%
EPS Incl Extra (Annual)$-2.45
Current Ratio (Annual)3.90x
Quick Ratio (Quarterly)2.56x
3-Month Avg Trading Volume0.16M
52-Week Price Return-15.10%
Revenue / Employee (TTM)$57,400
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)13.90x
Asset Turnover (Annual)0.02x
52-Week High$13.69
Operating Margin (5Y Avg)-2099.40%
EPS Excl Extra (Annual)$-2.45
CapEx CAGR (5Y)-26.66%
26-Week Price Return-45.84%
Quick Ratio (Annual)3.90x
13-Week Price Return-22.16%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.56x
Enterprise Value$486,200
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$26,700
Pretax Margin (Annual)-1092.36%
Cash / Share (Annual)$12.60
3-Month Return Std Dev79.45%
Net Income / Employee (TTM)$-1,101,500
ROE (Last FY)-45.18%
EPS Basic Excl Extra (Annual)$-2.45
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-8.70
ROI (TTM)-139.19%
P/S Ratio (TTM)6.46x
Pretax Margin (5Y Avg)-1719.87%
Revenue / Share (Annual)$0.22
Tangible BV / Share (Annual)$2.42
Price vs S&P 500 (52W)-42.15%
Year-to-Date Return-42.70%
5-Day Price Return-6.32%
EPS Normalized (Annual)$-2.45
ROA (5Y Avg)-78.47%
Net Profit Margin (Annual)-1106.72%
Month-to-Date Return-6.32%
Cash Flow / Share (TTM)$-1.86
EBITD / Share (Annual)$-8.81
Operating Margin (Annual)-4024.93%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-70.14%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-8.70
P/TBV (Quarterly)0.98x
P/B Ratio (Annual)1.07x
Pretax Margin (TTM)-1907.18%
Book Value / Share (Annual)$8.67
Price vs S&P 500 (13W)-32.66%
Beta2.35x
Revenue / Share (TTM)$0.45
ROE (TTM)-139.47%
52-Week Low$5.01
vGradeB
gGradeA
mGradeD
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-2.21est. -2.27
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.18
4.18
4.18
4.15
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALGSAligos Therapeutics, Inc. Common Stock | B | A | D | $4.91 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, including chronic hepatitis B, coronaviruses, and nonalcoholic steatohepatitis (NASH). The company maintains a pipeline of drug candidates targeting these areas of significant unmet medical need.